Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.

Zohra LayeghJill RuwaardRenske C F HebingMerel J L' AmiWilfred van der WeeleMike T NurmohamedCharlotte KrieckaertGertjan Wolbink

Published in: International journal of rheumatic diseases (2019)

In our population, 87% of patients continued Remsima during the follow-up period of approximately 2 years. Three patients restarted Remicade, while retaining stable DAS28-ESR.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
clinical practice
peritoneal dialysis
patient reported outcomes
systemic lupus erythematosus